Comprehensive Pharmaceutical Market Ratings
Our proprietary rating system evaluates the investment readiness of ASEAN markets based on regulatory transparency, infrastructure quality, and talent availability. This allows investors to allocate capital with precision.
Tier 1 Hubs
Markets with world-class infrastructure and streamlined regulatory pathways.
Growth Markets
Regions with high demand and rapidly improving regulatory frameworks.
Emerging Frontiers
High-risk, high-reward areas with significant untapped potential.
Regulatory Stability
Metrics focusing on the predictability of health authority approvals.
Understanding the Rating Metrics
We analyze a variety of quantitative and qualitative data points to assign market ratings. Key indicators include the time required for drug registration, the availability of PhD-level researchers, and the stability of currency exchange rates. A high rating in 'Infrastructure' indicates the presence of certified GMP facilities and reliable cold-chain logistics, which are essential for biologic products.
- Ease of doing business index for healthcare.
- Patent protection enforcement levels.
- Healthcare expenditure as a percentage of GDP.
- Availability of qualified clinical trial sites.
Ratings are updated quarterly to reflect changes in local legislation and macroeconomic shifts across the ASEAN bloc.
See also: Unlocking High Growth Pharma Markets in Southeast Asia · ASEAN Pharma Exit Strategies: 2026 Market Outlook · Comprehensive Funding Guides for Pharmaceutical Ventures · Real Impact: Client Testimonials from ASEAN Pharmaceutical Ventures